The biopharmaceutical sector has quickly rebounded after its dismal December performance, where it shed almost 8 percent in valuation, and it hasn't taken long for biotech investors to shake off their bear mindset. In fact, they have been generally more upbeat following the 37th Annual J.P. Morgan Healthcare Conference.